Hereditary haemochromatosis is a common autosomal recessive disorder of iron overload in Caucasian populations. Clinical manifestations usually occur in individuals homozygous for the C282Y mutation in the HFE gene product and who have developed significant iron loading. Current screening methods can detect affected individuals either prior to, or early during, disease evolution, enabling early introduction of phlebotomy treatment that can normalise life expectancy. Evaluation of possible iron overload, via measurement of serum transferrin saturation and ferritin level, is the most appropriate initial test for those subjects presenting clinically for evaluation. HFE genotyping, when combined with serum biochemical measurements, defines the presence of likely iron overload and the underlying genetic disorder and is the preferred initial screening modality for families of an affected individual. Definitive proof of iron overload requires measurement of hepatic iron concentration or total iron burden via therapeutic phlebotomy -elevated serum ferritin level alone is not adequate. We now recognize that the natural history of HH is not as discrete as previously believed, because genetic and environmental modifiers of disease penetrance are increasingly identified as influencing the clinical expression of HH. In fact, a minority of C282Y homozygotes develop classical "iron overload disease", although it has recently emerged that the disorder may predispose to breast and colorectal cancer. Uncertainties as to the true clinical impact of the condition at a population level lead to current recommendations of cascade screening of families of affected patients, case-finding in high-risk groups, such as patients with clinical manifestations consistent with the diagnosis, and a high level of clinical awareness in the community to facilitate early diagnosis. Generalised population screening is not presently recommended.
INTRODUCTION
Hereditary haemochromatosis (HH) is a common inherited disorder of iron metabolism affecting individuals primarily of northern European descent, which can result in iron overload, tissue injury and disease in a variable proportion of affected individuals. Whilst iron overload can result from a variety of primary or secondary causes (Table 1) , the term HH is restricted to defining iron overload disease which results from mutations in a limited range of key iron metabolism genes: Type 1 HH (HFE gene mutations), Type 2 (hepcidin or haemojuvelin gene mutations), Type 3 (transferrin receptor 2 gene mutations), and Type 4 (ferroportin gene mutations). The mechanisms responsible for the production of iron overload in the presence of these various types of HH are reviewed elsewhere, 1 sufficed to say that all result in impaired production of the key iron regulatory hormone hepcidin, impaired iron sensing and consequential inappropriately increased iron absorption from the gastrointestinal tract and release of iron from the bone marrow iron stores.
For the purposes of this article we will hereafter only refer to HFE-related HH. In order to discuss screening for HH, it is first necessary to understand the natural history and clinical expressivity of HH.
DISCOVERY AND CHARACTERISATION OF HFE-RELATED HH
During the latter years of the 20 th century, intensive genetic research led to the discovery of the candidate gene responsible for the majority of cases of for HH, termed HFE. 2 Two common mutations were identified in the gene product: first, tyrosine was substituted for cysteine at amino acid 282 (C282Y) and second, aspartate was substituted for histidine at amino acid 63 (H63D). Homozygosity for C282Y was observed in 85% to 90% of patients of northern European origin with typical HH, [2] [3] [4] [5] although it was relatively rare in non-Caucasian populations. 6 The C282Y mutation in the HFE gene product occurs in 1 in 7 individuals of northern European descent with 1 in 200 being homozygous for the mutation. 7 The more common H63D mutation, either alone or in homozygous form, has not been shown to be clinically important in terms of development of iron overload disease and will not be discussed further. 1 Following the initial discovery of the HFE gene, several cross-sectional studies indicated a wide variation in the biochemical penetrance of the disorder, as evidenced by elevated serum ferritin levels. When stratified according to gender, biochemical iron overload was found in 70% to 88% of men and 30% to 60% of women homozygous for the C282Y mutation. 3, [6] [7] [8] [9] High clinical penetrance was found in the original cross-sectional population study in Busseleton, Western Australia. Clinical penetrance (defined as hepatomegaly, skin pigmentation, or arthropathy) was present in 50% of C282Y homozygous subjects. 5 Twentyfive percent of C282Y homozygotes had hepatic fibrosis and 10% had cirrhosis on liver biopsy.
Interestingly, 25% of the homozygotes had no clinical symptoms or overt signs, with corresponding normal range serum ferritin over 4 years of follow-up.
A large Norwegian population-based study of more than 65,000 individuals aged 20 years or older reported a similar incidence of C282Y homozygosity as the Australian study, but clinical penetrance was lower. 10 Liver biopsy-proven moderate fibrosis and/or cirrhosis were seen in only 10% of cases. Fatigue and joint pain were the most common extrahepatic manifestations in 13% to 20% of newly diagnosed HH subjects, followed by impotence and diabetes mellitus (4%).
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A French clinic-based study also confirmed that 0.5% of the population were homozygous for C282Y, consistent with the earlier studies. 9 Ninety percent of male C282Y
homozygotes had at least one clinical symptom compared with 60% of females. Family history of iron excess and chronic fatigue were common clinical features for both genders. Twenty percent of homozygous subjects had arthritis, and 5% to 10% had diabetes or increased alanine transaminase levels. subjects, including all C282Y homozygotes and a stratified random sample of subjects from the remaining groups with other HFE genotypes, were evaluated in a follow-up study 12 years after initial recruitment. There were 203 C282Y homozygotes, 242 compound heterozygotes, 337 C282Y heterozygotes, and 147 H63D heterozygote/homozygotes identified. At baseline, 84% of male and 65% of female C282Y homozygotes had elevated serum ferritin levels, and 37% of male and 3% of female HH C282Y homozygotes had ferritin levels exceeding 1000 µg/L. 16, 19 C282Y homozygous males had up to a 50% likelihood of progression to serum ferritin levels exceeding 1000 µg/L after 12 years if they had baseline serum ferritin values of 300 to 1000 µg/L. With similar baseline values, C282Y homozygous females had up to a 20% likelihood of progression to serum ferritin levels exceeding 1000 µg/L after 12 years. For both genders, the risk of biochemical progression over a 12-year period to ferritin levels exceeding 1000 µg/L was less than 15% if they had normal baseline serum ferritin values. 16, 18 Furthermore, C282Y homozygotes who were likely to develop serum ferritin levels sufficient to place them at risk of iron overload-related disease generally did so by the age of 55 years.
The term "iron overload-related disease" was introduced by Allen et al. 16 homozygosity results in a two-fold increased risk of breast cancer in women 30, 31 and colorectal cancer in men and women. 30 Adding further to the emerging evidence base supporting a role for iron as a cofactor in carcinogenesis, Zacharski et al. 32 showed that a mild reduction of iron stores in normal individuals is associated with a reduced risk of cancer.
The risk of iron overload-related disease in C282Y/H63D compound heterozygotes is substantially less than that of C282Y homozygotes. Gurrin et al. 17, 18 reported a longitudinal 12-year clinical follow-up study of 180 untreated compound heterozygotes (84 males) compared with 330 randomly selected wild-type control subjects. Compared with controls, mean serum ferritin levels and transferrin saturation were significantly higher for both genders, although both were within normal ranges, consistent with earlier reports. 3, 33 Serum ferritin levels did not increase significantly in male or postmenopausal female compound heterozygotes after middle age. Only one male subject (who also had other liver disease risk factors) and none of the female subjects developed iron overload-related disease.
SCREENING FOR HH
The "gold standard" criteria for determination of appropriateness of generalised population screening for a disease have been defined by the World Health Organisation as: homozygous subjects will develop iron overload disease. [16] [17] [18] This equates to 1 in 20,000 females and 1 in 670 males of northern European origin suffering from iron overload disease consequential to C282Y homozygosity. The impact of the increased propensity to malignancy at a population level which is incurred through C282Y homozygosity remains to be defined.
Criterion 2.
Multiple studies demonstrate that the natural history is not completely predictable. Less than 15% of adult C282Y homozygotes who possess normal serum ferritin levels will progress to ferritin levels greater than 1000 μg/L. Up to 80% of females and 50% of males who possess serum ferritin levels of at least 1000 μg/L will show reductions of ferritin levels in the absence of treatment over a 12-year time-frame.
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Criteria 3 and 4. Hereditary haemochromatosis has a long, asymptomatic latent period during which genetic testing for HFE mutations and serum iron studies (transferrin saturation and ferritin level) can be used to identify those individuals most at risk of iron overload disease.
By the age of 55 years, 84% of male and 65% of female C282Y homozygotes will develop elevated serum ferritin levels, and 37% of male and 3% of female HH C282Y homozygotes will develop ferritin levels exceeding 1000 µg/L. 16, 18 Symptoms and signs of iron overload disease are most likely in those whose ferritin levels exceed 1000 µg/L.
Criteria 5, 6, 7 and 8. Phlebotomy therapy for HH was first described in 1950 and has remained the cornerstone of therapy. 35 In many countries the blood transfusion services provide therapeutic phlebotomy and the blood can be utilized for various products. There are no evidence-based guidelines on therapeutic phlebotomy for HH. Treatment is conventionally commenced once serum ferritin exceeds the normal range; 200 g/L in premenopausal women and 300 g/L in postmenopausal women and men. The goal is to reduce the serum ferritin level to low normal range, usually 20 -100 g/L. In the induction phase, 1 unit (400-500 mls) of blood, equivalent to 200-250 mg of iron, can be safely removed weekly. Serum ferritin should be monitored after each 1-2 g of iron removed. Patients then undergo maintenance phlebotomy, which varies between individuals in frequency of requirement to keep serum ferritin levels in the range 20-100 g/L. [36] [37] [38] [39] [40] Levels lower than this may be associated with symptoms of iron deficiency. 40 The benefit of phlebotomy has been clearly demonstrated in cohort studies. [42] [43] [44] [45] [46] Survival of clinically diagnosed HH patients who have undergone phlebotomy therapy is greater than those who are not adequately de-ironed. 42 It is also thought that pre-emptive therapy prevents complications, although treatment efficacy has never been subjected to randomized controlled studies. In the absence of complications of cirrhosis or diabetes, the life expectancy of treated patients approaches is similar to that of the age and gender-matched general population. 44, 45 Phlebotomy improves liver transaminases, skin pigmentation and liver fibrosis. Up to 50% of patients with biopsy proven liver fibrosis show regression with optimal effect occurring when baseline fibrosis is mild. 26, 39 Extra-hepatic manifestations such as hypogonadism, cirrhosis, deforming arthropathy and diabetes requiring insulin are usually irreversible. 46 Phlebotomy is generally accepted as being indicated in homozygotes with ferritin levels >1000 g/L. 18 Recent studies indicate that progression of iron overload is not universal. In males, the highest risk of progression is in those subjects with ferritin levels > 1000g/L and transferrin saturation > 95%. 18 Females have a much lower risk of progression, with the likelihood being predominantly influenced by menopausal status.
The current AASLD guidelines advocate regular phlebotomy to maintain the serum ferritin between 50 and 100 g/L in asymptomatic individuals with homozygous HH, markers of iron overload, and histological evidence of potentially toxic levels of hepatic iron. 40 However, more recent Australian data suggests an alternative approach might be to monitor HH subjects with serum ferritin levels between the upper limit of normal and 1000 g/L. 16, 18 These studies demonstrated that the risk of development of iron-overload disease in C282Y
homozygous subjects with ferritin levels in the range between upper limit of normal and 1000 g/L was no greater than that observed in C282Y homozygotes with normal ferritin or wildtype controls. 17, 18 Less that 50% of male C282Y homozygotes and less than 20% of female C282Y homozygotes with serum ferritin levels less than 1000g/L at the age of 55 years progress to levels greater than 1000g/L by the age of 67 years.
Criterion 9. The ultimate determinant of implementation of a publicly funded screening program is cost. There is no doubt that genetic and/or biochemical screening will discover C282Y homozygotes at various stages of disease evolution, some of whom will benefit from early intervention. Early cost-effectiveness modeling attempts were based on higher levels of disease expression than is apparent from the more recent population studies. 16, 47, 48 Cascade screening of male individuals within affected families following the initial diagnosis of a proband has been demonstrated to be the most cost-effective strategy (41,000
€/life year gained (LYG)), whereas sequential population screening using either biochemical or genetic testing cost in the order of 124,000 or 161,000 €/LYG, respectively. 49 Screening within families provides a 25% likelihood of returning other affected individuals. [49] [50] [51] Gagne et al (2007) concluded that provided there was at least 70% biochemical expression with subsequent development of clinical sequelae in 5% of these individuals, screening was cost-effective. 48 These assumptions most closely reflect the natural history of disease progression in males. 16 Due to the limited expressivity in females compared with males, Phatak et al (2008) also recommended screening be focused on males over the age of 25 years and of northern European descent, or those with a family history of HH. 47 A high level of clinical awareness which leads to "case-finding" for HH is advocated in individuals presenting with clinical manifestation known to be associated with HH. These include chronic liver disease, diabetes mellitus and arthritis. 1, 16 Routine screening per se has not been proven to be beneficial in subjects with diabetes mellitus. 52 Up to 24% of subjects with HH have a typical bilateral peripheral arthropathy affecting metacarpophalangeal joints, hips or knees. C282Y homozygous (common, high risk for iron overload) C282Y/H63D compound heterozygous (common, low risk for iron overload)
Other HFE mutations (common, low risk for iron overload) 
Miscellaneous
Congenital alloimmune hepatitis (neonatal iron overload)
